Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 2020 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 11/1/1997


1.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8, POG-9410


2.		Phase II/III Chemotherapy with Streptozotocin plus 5-FU or ADR vs Chlorozotocin for Metastatic, Unresectable, or Recurrent Primary Islet Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified				NCI				EST-3278 EST-3278


3.		Phase II-III Chemotherapy with BLEO/DTIC/VBL/ADR/PRED or NM/VCR/PCB/PRED Plus Radiotherapy for Advanced Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								DFCI-75100


4.		Phase II-III Chemotherapy with Hexamethylmelamine and L-Phenylalanine Mustard for Stage III and IV Ovarian Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								DFCI-75118

Last Modified: 7/6/2007


5.		Phase II-III FAM (5-FU/ADR/MITO) vs V-FAM (FAM/VCR) vs Phase II Agent Chemotherapy for Advanced Gastric Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-7841


6.		Phase II-III HMM vs FAC (5-FU/ADR/CTX) Chemotherapy for Advanced Transitional Cell Bladder Cancer with Impaired Renal Function

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified				NCI				SWOG-7904 SWOG-7904

Last Modified: 6/1/1997


7.		Phase II-III Chemotherapy with CAP (CTX/ADR/CACP) vs AMSA for Advanced Transitional Cell Cancer of the Urinary Bladder (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-7922

Last Modified: 5/23/2007


8.		Phase II/III Chemotherapy with MVP (MITO/VBL/CACP) vs CHIP vs CBDCA vs VBL/CACP vs MVP-CAMP (MITO/VBL/CACP/CTX/ADR/MTX/PCB) in Patients with Metastatic (Stage III) non-Small Cell Bronchogenic Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-1583 EST-1583


9.		Phase II/III CAP (CTX/ADR/CACP) Chemotherapy with or without Radiotherapy for Inoperable non-Small Cell Lung Cancer Comparing Weekly Intravenous ADR vs a 24-Hour Infusion Every 3 Weeks

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								MDA-DT-8102


10.		Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 65								WCCC-CO-7711R NCI-D80-048-183

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute